lymphoma Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 13, 2022 Epigenetic Age Acceleration Underlies Cognitive Decline in Survivors of Childhood Hodgkin Lymphoma Premium Dec 12, 2022 ASH Data Suggests CAR T is Best Option for Lymphoma Patients Expressing Both MYC, BCL-2 Premium Dec 8, 2022 Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences Nov 16, 2022 Aussie Variant Classification Effort Aims to Reduce Uncertainty in Hereditary Blood Cancer Diagnosis Premium Nov 7, 2022 Automation Offers No Easy Answers to CAR T-Cell Supply Shortfalls Premium Nov 1, 2022 Monte Rosa Doses First Patient in Phase I/II Trial of MRT-2359 Oct 28, 2022 AbbVie, Genmab File for Bispecific Antibody Approval in US, EU for CD20-Positive Advanced Lymphoma Oct 28, 2022 Gilead Sciences' Oncology Sales Soar 79 Percent in Q3 Premium Oct 19, 2022 Tumor Analysis Platform Predicts Personalized Drug Combos for Non-Hodgkin Lymphoma Patients Premium Oct 18, 2022 Gilead Sciences Nets Second-Line Yescarta Approval for Lymphoma Patients in Europe Oct 11, 2022 ONI, UPenn Partner on Microscopy-Based CAR T-Cell Therapy Biomarker Research Sep 19, 2022 EMA's CHMP Recommends Gilead's Yescarta for Second-Line Lymphoma Aug 26, 2022 Incyte's Pemazyre Nets FDA Approval for Rare Blood Cancer Aug 3, 2022 Gilead Sciences' Q2 Oncology Sales Jump 71 Percent Driven by Trodelvy, Cell Therapies Premium Jul 27, 2022 BMS Reports Q2 Growth in CAR T-Cell Therapies Despite Manufacturing Hurdles Premium Jul 22, 2022 Leukemia and Lymphoma Society PedAL Trial Aims to Advance Pediatric Precision Oncology Premium Jul 13, 2022 Mission Bio Working to Bring Tapestri Single-Cell Sequencing Platform to Precision Oncology Premium Jul 11, 2022 Legend Biotech Shutters Trial of CD4-Directed CAR T-Cell Therapy for T-Cell Lymphoma Jun 29, 2022 Leukemia and Lymphoma Society Launches Master Protocol Trial in Childhood Leukemia Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
